Validation of microrna‐199b as a promising predictor of outcome and response to neoadjuvant treatment in locally advanced rectal cancer patients

Abstract

The absence of established predictive markers with value to anticipate response to neoadjuvant 5‐fluorouracil (5‐FU)‐based chemoradiotherapy (CRT) represents a current major challenge in locally advanced rectal cancer (LARC). The tumor suppressor microRNA (miR)‐199b has been reported to play a key role determining 5‐FU sensitivity of colorectal cancer cells through the regulation of several signaling pathways, and has emerged as a novel molecular target to overcome the 5‐FU resistant phenotype. Moreover, miR‐199b downregulation was described as a common alteration that predicts lack of response to preoperative CRT in LARC but this issue needs to be confirmed in independent larger cohorts. Here, we evaluate the clinical impact of miR‐199b in LARC and perform additional analyses to further clarify its potential relevance as novel marker in this disease. Thus, miR‐199b expression was quantified by real‐time‐PCR in a cohort of 185 LARC patients, observing this miR downregulated in 22.2% of cases and significantly associated with higher tumor size (p= 0.026) and positive lymph node after CRT (p= 0.005), and higher pathological stage (p= 0.004). Notably, this alteration showed a strong independent predictive value of poor pathological response to neoadjuvant CRT (p= 0.004). Moreover, the subgroup of cases with low miR‐199b levels had a markedly shorter overall (p< 001) and event‐free survival (p< 0.001), and multivariate analyses showed that miR‐199b deregulation represents an independent prognosticator for patient outcome in LARC. Interestingly, the prognostic impact of this miR was strongly significant in both younger and elderly patients, and was very effective determining patient recurrence (p= 0.004). Finally, we compared miR‐199b expression profiles in a set of cases with pre and post‐treatment samples available, observing that only a minimal response leads to miR‐199b increase levels, further suggesting its potential clinical and therapeutic relevance as a promising marker and novel molecular target for the management of LARC.